Feed HROW
HR

Harrow Health, Inc. HROW · NASDAQ

$27.68 +1.47% (+$0.40)

Market cap
$1.04B
Enterprise value
$1.25B
P/E
-
Forward P/E
-
PEG
-
P/S
3.8x
P/FCF
182.5x
EV/EBITDA
279.8x
ROIC
2.0%
Gross margin
73.3%
Net margin
-13.5%
Dividend yield
-
Payout ratio
-
Net debt/EBITDA
48.4x
Beta
0.24
Free float
77.2%

About the company

Harrow Health, Inc. is a pharmaceutical company primarily focused on providing affordable and innovative drugs and healthcare products. The company specializes in the development and commercialization of pharmaceuticals and medical devices in the fields of ophthalmology, dermatology, and neurology. Their portfolio includes a wide range of therapeutic products, including generics, branded drugs, and medical devices, aimed at treating various health conditions and diseases. Harrow Health, Inc. focuses on providing affordable and quality medications for patients and strengthening its position in the pharmaceuticals and healthcare products market.

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

CEO

Mark L. Baum

Employees

373

Headquarters

Nashville

Valuation

Is today's price reasonable?

Growth and estimates

Is it growing, and what comes next?

Profitability and quality

How much of the revenue is left, and how well does the company use its capital?

Financial health

Can it carry its debt?

Capital and dividends

What does the company do with the money it earns?

Analysts

What do the professionals think, and is it changing?

Owners and insiders

Who holds the stock, and what is management doing?

Segments

Which part of the company is growing?

Peer comparison

How does it compare with similar companies?

Price and risk

How does the stock behave?

Statements

Every number

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.